Kintegral Advisory LLC Trims Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Kintegral Advisory LLC lowered its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 32.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,311 shares of the medical instruments supplier's stock after selling 2,115 shares during the period. Kintegral Advisory LLC's holdings in Becton, Dickinson and Company were worth $987,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares in the last quarter. Hara Capital LLC boosted its holdings in shares of Becton, Dickinson and Company by 26.4% during the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock valued at $76,000 after buying an additional 70 shares in the last quarter. Mission Wealth Management LP bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $262,000. Assetmark Inc. boosted its holdings in shares of Becton, Dickinson and Company by 51.0% during the 4th quarter. Assetmark Inc. now owns 51,180 shares of the medical instruments supplier's stock valued at $11,611,000 after buying an additional 17,292 shares in the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $21,607,000. Institutional investors own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Wall Street Zen cut shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. William Blair cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Raymond James Financial lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their price target for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Wells Fargo & Company lowered Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and a consensus price target of $219.22.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded up $1.65 during mid-day trading on Tuesday, reaching $174.60. The company's stock had a trading volume of 1,908,132 shares, compared to its average volume of 2,069,888. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The firm's fifty day moving average price is $172.66 and its two-hundred day moving average price is $206.96. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The stock has a market cap of $50.04 billion, a P/E ratio of 33.32, a PEG ratio of 1.31 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same quarter in the previous year, the firm earned $3.17 EPS. Becton, Dickinson and Company's revenue was up 4.5% on a year-over-year basis. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.